Summary
This is the first long-term study of pindolol in a population-based sample of men with newly diagnosed hypertension.
Eighty-two patients, with a diastolic pressure of 100 mm Hg or more, were identified after screening 6000 men. Many patients were overweight. 82 population controls, matched by sex, age and body mass index, were also recruited. Fourty-eight per cent of the patients and 25% of the controls had a family history of hypertension.
Serum triglyceride and urate values were higher in patients than controls at the baseline investigation. Seventy-four patients were followed for 1 year. The dose of pindolol averaged 7.7 mg once daily after 1 year.
The diastolic blood pressure was reduced by 13.4 mm Hg. The target pressure of 95 mm Hg or less was achieved in 89% of the patients. The HDL-cholesterol concentration was normal and did not change, whereas the LDL-cholesterol concentration decreased by 0.15 mmol · l−1 during treatment. The total triglyceride values increased transiently up to 6 months, but no significant increase was seen after one year.
It is concluded that pindolol had no adverse effect on serum cholesterol and its HDL- and LDL-fractions during 1 year of treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Wilcox RG, Mithcell JR, Hampton JR (1986) Treatment of high blood pressure. Should clinical practice be based on results of clinical trials. Br Med J 293: 433–437
Wolinsky H (1987) The effects of beta-adrenergic agents on blood lipid levels. Clin Cardiol 10: 564–566
Neaton JD, Kuller LH, Wentworth D, Borhani N (1984) Total and cardiovascular disease mortality in relation to cigarette smoking, serum cholesterol concentration and diastolic blood pressure. Am Heart J 108: 759–769
Carlson LA, Böttiger LE (1985) Risk factors for ischemic heart disease in men and women. Acta Med Scand 218: 207–211
Andersen KM, Castelli WP, Levy D (1987) Cholesterol and mortality — 30 years of follow-up from the Framingham study. J Am Med Assoc 257: 2176–2180
Multiple risk factor intervention trial research group (1986) Coronary heart disease death, nonfatal acute myocardial infarction and other clinical outcomes in the multiple risk factor intervention trial. Am J Cardiol 58: 1–13
Carlson LA, Rosenhammar G (1988) Reduction of mortality in the Stockholm ischemic heart disease prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 223: 405–418
Ballantyne D, Ballantyne FC (1983) Thiazides, beta-blockers and lipoproteins. Postgrad Med J 59: 483–488
van Brummelen P (1983) The relevance of intrinsic sympaticomimetic activity for beta-blocker-induced changes in plasma lipids. J Cardiovasc Pharmacol 5 [Suppl 1]: S51-S55
Miller NE (1987) Effects of adrenoceptor-blocking drugs on plasma lipoprotein concentrations. Am J Cardiol 60: 17E-23E
Northcote R, Ballantyne D (1987) Beta-adrenoceptor blockade and plasma lipoproteins, comparison of the effects of propranolol and pindolol on plasma lipoproteins including high-density lipoprotein subfraction. Clin Sci 72: 549–556
Krauss R (1982) Regulation of high density lipoprotein levels. Med Clin North Am 66: 403–430
WHO Expert Committee on Diabetes Mellitus (1980) WHO Techn Rep Ser No 646
Carlson LA (1982) Fish eye disease: A new familial condition with massive corneal opacities and dyslipoproteinemia. Eur J Clin Invest 12: 41–53
Zacest R, Barrow KCG, Halloran MW, Wilson LL (1981) Relationship of psychological factors to failure of antihypertensive drug treatment. Aust NZ J Med 11: 501–507
Samuelsson O, Andersson O, Wilhelmson L, Berglund G (1982) Treatment of hypertension at an outpatient hypertension clinic. Blood pressure control, dropout rate, and side-effects. Prev Med 11: 521–535
Grundy S (1986) Cholesterol and coronary heart disease. J Am Med Assoc 256: 2849–2858
Castelli W (1986) The triglyceride issue: A view from Framing-ham. Am Heart J 112: 432–437
Gretzer I, Rössner S (1986) Long-term effects of pindolol on serum lipids in hypertensive patients. Acta Med Scand 219: 367–370
Northcote R (1988) Beta-blockers, lipids and coronary atherosclerosis: Fact or fiction. Br Med J 296–297
Rhoades G, Kagan A (1983) The relation of coronary disease, stroke and mortality to weight in youth and middle age. Lancet 1: 492–495
Larsson B, Svärdsudd K, Welin L, Wilhelmsen L, Björntorp P, Tibblin G (1984) Abdominal tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up participants in the study of men born in 1913. Br Med J 288: 1401–1404
Carlson LA, Holmquist L, Nilsson-Ehle P (1986) Deficiency of hepatic lipase activity in post-heparin plasma in familial hyper alfa-triglyceridemia. Acta Med Scand 219: 435–447
Study group, European Atherosclerosis Society (1987) Strategies for the prevention of coronary heart disease: A policy statement for the European Atherosclerosis Society. Eur Heart J 8: 77–88
Kristensson H, Trell E, Fex G, Hood B (1980) Serum gammaglutamyltransferase: Statistical distribution in middle-aged male population and evaluation of alcohol habits in individuals with elevated levels. Prev Med 9: 108–119
Klatsky AL, Friedman GD (1984) The role of alcohol in the epidemiology of hypertension — is alcohol associated hypertension a common preventable disease? Ann Clin Res 16 [Suppl 43]: 89–96
Criqui M (1987) The roles of alcohol in the epidemiology of cardiovascular diseases. Acta Med Scand 717 Suppl: 7 3–85
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Terént, A., Ribacke, M. & Carlson, L.A. Long-term effect of pindolol on lipids and lipoproteins in men with newly diagnosed hypertension. Eur J Clin Pharmacol 36, 347–350 (1989). https://doi.org/10.1007/BF00558293
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00558293